Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 陈力元教授 (内科及药物治疗学系) |
| 杨明明教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1111/j.1440-1746.2012.07280.x |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/26WOS source URL
其它资讯
摘要Reactivation of hepatitis B virus (HBV) infection is a known complication during and after anti-cancer therapy. This condition can affect two patient populations: it is most commonly seen in patients who are seropositive for hepatitis B surface antigen (HBsAg), but it is also being increasingly reported among patients who are HBsAg-negative but who have prior infection, as evident by seropositive status for antibody to hepatitis B core antigen (anti-HBc), irrespective of their anti-HBs (antibody to HBsAg) status. The clinical course can vary from asymptomatic hepatitis to fulminant hepatic failure that can be potentially fatal. With the increasing use of biological agents in addition to potent cytotoxic chemotherapy in the armamentarium of anti-cancer treatments, reactivation of hepatitis B has become a common clinical situation that is faced by both oncologists and hepatologists especially in HBV endemic areas. In this review, we discuss the clinical course of reactivation in the two HBV-infected sub-populations, and the role of anti-virals in the prevention and management of HBV reactivation in association with cytotoxic chemotherapy and biological therapies.
着者Yeo W, Chan HLY
期刊名称Journal of Gastroenterology and Hepatology
出版年份2013
月份1
日期1
卷号28
期次1
出版社Wiley: 12 months
页次31 - 37
国际标準期刊号0815-9319
电子国际标準期刊号1440-1746
语言英式英语
关键词hepatitis B virus; immunosuppression; reactivation
Web of Science 学科类别Gastroenterology & Hepatology; GASTROENTEROLOGY & HEPATOLOGY
